PSMA PET/CT ligands labelled with 18F and 68Ga have certainly revolutionized the management of metastatic prostate cancer selecting patients who may benefit from targeted systemic radionuclide therapy. Here, FOLH1 is linked to metastatic prostate carcinoma.